Log in

NASDAQ:GHGuardant Health Stock Price, Forecast & News

$85.21
-2.31 (-2.64 %)
(As of 07/10/2020 04:00 PM ET)
Add
Compare
Today's Range
$85.01
Now: $85.21
$87.26
50-Day Range
$76.44
MA: $84.56
$96.91
52-Week Range
$55.90
Now: $85.21
$112.21
Volume404,500 shs
Average Volume1.14 million shs
Market Capitalization$8.06 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.61
Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers liquid biopsy tests for advanced stage cancer, such as Guardant360, a molecular diagnostic test that measures various cancer-related genes; and GuardantOMNI, a broader gene panel, including genes associated with homologous recombination repair deficiency and biomarkers for immuno-oncology applications. It also provides LUNAR-1 for minimal residual disease and recurrence detection in cancer survivors. In addition, the company is developing LUNAR-2 for early detection of cancer in higher risk individuals. Further, it offers development services, including companion diagnostic development and regulatory approval, clinical trial referral, and liquid biopsy testing development and support services to biopharmaceutical companies and medical institutions. Guardant Health, Inc. was incorporated in 2011 and is headquartered in Redwood City, California.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.57 out of 5 stars


Industry, Sector and Symbol

Industry Medical laboratories
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone855-698-8887

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$214.38 million
Book Value$8.50 per share

Profitability

Net Income$-75,650,000.00

Miscellaneous

Employees454
Market Cap$8.06 billion
Next Earnings Date8/4/2020 (Estimated)
OptionableNot Optionable

Receive GH News and Ratings via Email

Sign-up to receive the latest news and ratings for GH and its competitors with MarketBeat's FREE daily newsletter.

Guardant Health (NASDAQ:GH) Frequently Asked Questions

How has Guardant Health's stock been impacted by COVID-19 (Coronavirus)?

Guardant Health's stock was trading at $62.95 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, GH stock has increased by 35.4% and is now trading at $85.21. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Guardant Health?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Guardant Health in the last year. There are currently 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Guardant Health.

When is Guardant Health's next earnings date?

Guardant Health is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Guardant Health.

How were Guardant Health's earnings last quarter?

Guardant Health Inc (NASDAQ:GH) released its quarterly earnings results on Thursday, May, 7th. The company reported ($0.29) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.39) by $0.10. The company had revenue of $67.50 million for the quarter, compared to the consensus estimate of $55.45 million. Guardant Health had a negative net margin of 30.27% and a negative return on equity of 9.24%. The firm's revenue for the quarter was up 83.9% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.30) EPS. View Guardant Health's earnings history.

What price target have analysts set for GH?

8 analysts have issued 12-month price targets for Guardant Health's stock. Their forecasts range from $100.00 to $135.00. On average, they anticipate Guardant Health's share price to reach $116.14 in the next year. This suggests a possible upside of 36.3% from the stock's current price. View analysts' price targets for Guardant Health.

Has Guardant Health been receiving favorable news coverage?

Media stories about GH stock have been trending somewhat negative on Saturday, InfoTrie Sentiment reports. The research firm identifies positive and negative press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Guardant Health earned a media sentiment score of -1.8 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the near future. View the latest news about Guardant Health.

Who are some of Guardant Health's key competitors?

What other stocks do shareholders of Guardant Health own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Guardant Health investors own include NVIDIA (NVDA), Alibaba Group (BABA), Trade Desk (TTD), Roku (ROKU), Paypal (PYPL), Twilio (TWLO), Okta (OKTA), Square (SQ), Shopify (SHOP) and Alteryx (AYX).

Who are Guardant Health's key executives?

Guardant Health's management team includes the following people:
  • Mr. AmirAli Talasaz, Chairman, Pres & COO (Age 40)
  • Dr. Helmy Eltoukhy Ph.D., Co-Founder, CEO & Director (Age 40)
  • Mr. Michael J. Wiley, Chief Legal Officer (Age 44)
  • Mr. Derek A. Bertocci, Chief Financial Officer (Age 65)
  • Dr. Richard B. Lanman, Chief Medical Officer (Age 64)

When did Guardant Health IPO?

(GH) raised $200 million in an IPO on Thursday, October 4th 2018. The company issued 12,500,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan and BofA Merrill Lynch acted as the underwriters for the IPO and Cowen, Leerink Partners and William Blair were co-managers.

What is Guardant Health's stock symbol?

Guardant Health trades on the NASDAQ under the ticker symbol "GH."

Who are Guardant Health's major shareholders?

Guardant Health's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Carnegie Capital Asset Management LLC (0.09%), Envestnet Asset Management Inc. (0.05%), Ipswich Investment Management Co. Inc. (0.02%), Arden Trust Co (0.01%) and Mount Yale Investment Advisors LLC (0.00%). Company insiders that own Guardant Health stock include Amirali Talasaz, Bluebird (Cayman) Ltd Svf, Derek A Bertocci, Helmy Eltoukhy, Ian T Clark, Michael J Wiley, Richard B Lanman, Samir Kaul, Stanley J Meresman, Timothy P Eckersley and Vision Fund (Aiv M1) Softbank. View institutional ownership trends for Guardant Health.

Which institutional investors are buying Guardant Health stock?

GH stock was purchased by a variety of institutional investors in the last quarter, including Carnegie Capital Asset Management LLC, Arden Trust Co, Mount Yale Investment Advisors LLC, Envestnet Asset Management Inc., and Ipswich Investment Management Co. Inc.. View insider buying and selling activity for Guardant Health.

How do I buy shares of Guardant Health?

Shares of GH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Guardant Health's stock price today?

One share of GH stock can currently be purchased for approximately $85.21.

How big of a company is Guardant Health?

Guardant Health has a market capitalization of $8.06 billion and generates $214.38 million in revenue each year. The company earns $-75,650,000.00 in net income (profit) each year or ($0.84) on an earnings per share basis. Guardant Health employs 454 workers across the globe.

What is Guardant Health's official website?

The official website for Guardant Health is www.guardanthealth.com.

How can I contact Guardant Health?

Guardant Health's mailing address is 505 PENOBSCOT DR., REDWOOD CITY CA, 94063. The company can be reached via phone at 855-698-8887.

This page was last updated on 7/11/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.